Poly Medicure

    POLYMED
    Pharma
    ₹1,654.50
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹16,770 Cr

    P/E
    52.74
    Day range
    ₹1,640.10 – ₹1,686.20
    52-week range
    ₹1,182.00 – ₹2,024.00
    Volume
    55,639
    Open
    ₹1,640.10
    Prev close
    ₹1,649.60

    Latest results · Q2 FY27(consolidated)Revenue ₹581 Cr+30.8%Profit ₹95 Cr+3.6%Margin 16.4%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 43 / 100

    Factor percentiles

    Value32
    Quality45
    Momentum57
    Low volatility39

    Derived metrics

    Earn. yield
    1.9%
    Graham no.
    ₹471.15
    vs Graham
    -71.5%
    ROE ÷ P/B
    2.1%
    12-1 mom.
    -14.4%
    Return / vol
    -0.27
    Magic Formula
    #514
    Piotroski
    2/6
    FCF yield
    -0.4%
    PEG
    14.55

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Poly MedicurePOLYMED₹16,770 Cr52.745.2310.9%12.0%24.0%0.13+30.9%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 1h ago

    Headlines about Poly Medicure from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    54.0
    Price / Book
    5.14
    ROE (FY26)
    10.9%
    ROCE (latest year)
    12%
    Dividend yield
    0.21%

    Moving averages (NSE)

    20-day
    ₹1,554.94
    Price above
    50-day
    ₹1,621.51
    Price above
    200-day
    ₹1,546.84
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +18.9%
    Profit 3Y CAGR
    +21.5%
    Revenue YoY (Sep 2026)
    +30.9%
    Profit YoY (Sep 2026)
    +3.3%
    Operating margin
    24.0%
    Net margin
    16.4%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr200 Cr400 Cr600 Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%15%30%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • DII
    • FII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-2K Cr-1K Cr0 Cr1K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr1K Cr2K Cr3K Cr4K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY18FY19FY20FY21FY22FY23FY24FY25FY26FY27₹0₹1₹2₹3₹4

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales340378385420424441403444494535525581
    Expenses249282281305310321298329382424400443
    Operating Profit9096104115114119106115111110125138
    OPM %27%26%27%27%27%27%26%26%23%21%24%24%
    Other Income171517272427433521193530
    Interest333332336667
    Depreciation161620212121232529383635
    Profit before tax8892981181131231231229885117125
    Tax %26%26%25%26%25%25%24%25%27%24%27%24%
    Net Profit656874878592939271658595
    EPS in Rs₹6.78₹7.12₹7.71₹8.63₹8.41₹9.06₹9.19₹9.06₹7.00₹6.54₹8.49₹9.39

    From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days103

    +31 days since Mar 2021

    Inventory Days323

    +106 days since Mar 2021

    Days Payable91

    -20 days since Mar 2021

    Cash Conversion Cycle335

    +156 days since Mar 2021

    Working Capital Days105

    +31 days since Mar 2021

    Strengths, risks & growth

    Poly Medicure Limited is an India-based manufacturer and exporter of medical devices. The Company exports plastic medical disposables/surgical devices. [1]

    Strengths

    None flagged by the checklist.

    Risks

    • Company has a low return on equity of 13.3% over last 3 years.
    • Debtor days have increased from 83.9 to 103 days.

    Compounded Sales Growth

    10 Years
    +16%
    5 Years
    +19%
    3 Years
    +19%
    TTM
    +25%

    Compounded Profit Growth

    10 Years
    +20%
    5 Years
    +16%
    3 Years
    +19%
    TTM
    -13%

    Stock Price CAGR

    10 Years
    +25%
    5 Years
    +13%
    3 Years
    +3%
    1 Year
    -13%

    Return on Equity

    10 Years
    +15%
    5 Years
    +14%
    3 Years
    +13%
    Last Year
    +10%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter62.42%62.42%62.42%62.41%-0.01 pp
    FII9.41%5.92%5.56%5.36%-0.20 pp
    DII13.84%15.60%16.08%15.90%-0.18 pp
    Public14.34%16.08%15.94%16.33%+0.39 pp

    Filed with NSE for Sept 2026: promoters 62.42%, public 37.58%

    Analysts & fund holdings

    80%
    80% recommend buy
    5 analysts cover the stock
    Valuation vs Health Care Equipment & Supplies
    P/E52.7 vs 45.1
    Sector P/B6.03
    Beta1.00

    Who holds the shares, quarter by quarter

    Mutual funds 9.77% (+0.16 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters62.4%
    • Foreign institutions5.3%
    • Mutual funds9.8%
    • Insurance2.3%
    • Other domestic institutions3.8%
    • Retail7.7%
    • Others8.6%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Quant Small Cap Fund3.78%1.87%-0.31 pp
    UTI Flexi Cap Fund1.18%0.88%-0.11 pp
    HSBC Midcap Fund1.07%1.07%+0.11 pp
    SBI Healthcare Opp Fund0.54%1.53%-0.49 pp
    SBI MNC Fund0.52%1.42%-0.05 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    41.4%
    Downside volatility
    38.1%
    Worst 5% of days
    4.5%
    Average of that tail
    5.7%
    Max drawdown (1Y)
    42.3%
    Below its peak
    19.9%

    Against the market

    Beta vs Nifty 50
    0.89
    Correlation
    0.29
    Relative strength (3M)
    -8.4%
    ATR (14)
    3.3%

    Return

    Return 1M
    +3.8%
    Return 3M
    -4.6%
    Return 6M
    +13.9%
    Return 1Y
    -11.2%
    vs 200-day average
    +7.0%

    Momentum

    RSI (14)
    58.9
    MACD histogram
    19.68
    Stochastic %K
    81.3
    ADX (14)
    26.3
    +DI / −DI
    22.8 / 15.9
    Money flow index
    74.3

    Participation

    Delivery (20d avg)
    49.7%
    vs its 60-day baseline
    +1.4 pts
    Volume vs 20-day
    -0.5σ
    Close vs day's VWAP
    -0.6%
    52-week position
    53 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    2 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — failed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — failed
    • Asset turnover improving — passed
    Free cash flow
    -₹62 Cr
    FCF yield
    -0.4%
    Cash conversion
    0.77
    Accruals ratio
    0.019
    Net debt
    ₹354 Cr
    Net debt / equity
    0.11
    EV / sales
    8.02
    PEG
    14.55
    Capex intensity
    16.4%
    Revenue CAGR
    20.1%
    Profit CAGR
    2.4%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • dividend
      ₹3.50

      Dividend - Rs 3.50 Per Share

      28 Aug 2026
      ex-date
    • dividend
      ₹3.50

      Dividend - Rs 3.50 Per Share

      18 Sept 2025
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting/Dividend - Rs 3 Per Share

      19 Sept 2024
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting/Dividend - Rs 3 Per Share

      21 Sept 2023
      ex-date
    • dividend
      ₹2.50

      Annual General Meeting/Dividend - Rs 2.50 Per Share

      16 Sept 2022
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      16 Sept 2021
      ex-date
    • dividend
      ₹2.50

      Dividend - Rs 2.50 Per Share

      16 Sept 2021
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      21 Sept 2020
      ex-date
    • dividend
      ₹2.00

      Interim Dividend - Rs 2 Per Share

      27 Feb 2020
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/Dividend - Rs 2 Per Share

      13 Sept 2019
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/Dividend- Rs 2 Per Share (Purpose Revised)

      18 Sept 2018
      ex-date
    • dividend
      Not available — not reported in this filing

      Dividend- Re 0.50 Per Share

      20 Sept 2017
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting/Dividend - Re 0.50 Per Share

      20 Sept 2017
      ex-date
    • bonus
      Not available — not reported in this filing

      Bonus 1:1

      24 Mar 2017
      ex-date
    • dividend
      Not available — not reported in this filing

      Interim Dividend Re 1/- Per Share

      15 Feb 2017
      ex-date
    • dividend
      Not available — not reported in this filing

      Interim Dividend Re 1/- Per Share (Purpose Revised)

      11 Nov 2016
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting/Dividend - Re 0.50 Per Share (Purpose Revised)

      19 Sept 2016
      ex-date
    • dividend
      ₹2.50

      Interim Dividend - Rs 2.50/- Per Share (Purpose Revised)

      17 Mar 2016
      ex-date
    • dividend
      ₹2.50

      Annual General Meeting/Dividend Rs 2.50 Per Share

      18 Sept 2015
      ex-date
    • split
      Not available — not reported in this filing

      Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 5/- Per Share

      2 Feb 2015
      ex-date

    Company announcements

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Please find enclosed Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018

    Insider Trading / SAST
    Closure of Trading Window

    The Company Informed the Exchange about the Closure of Trading Window.

    Company Update
    Intimation For The Schedule Of Investors/Analysts Call/Meet.

    Enclosed

    Company Update
    Intimation For The Schedule Of Investors/Analysts Call/Meet.

    Enclosed

    Company Update
    Intimation For The Schedule Of Investors/Analysts Call/Meet.

    Enclosed

    Company Update
    Intimation For The Schedule Of Investors/Analysts Call/Meet.

    Enclosed

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Scrutinizer Report and Voting Results

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Outcome of the 31st Annual General Meeting of the Poly Medicure Limited.

    Company Update
    Intimation For The Schedule Of Investors/Analysts Call/Meet.

    Enclosed

    Company Update
    Intimation On Rescheduling Of Investor/Analyst Meet.

    Enclosed

    Company Update
    Intimation For The Schedule Of Investors/Analysts Call/Meet.

    Enclosed

    Company Update
    Investors Call Scheduled To Be Held On 20 August, 2026 Is Cancelled - Updates On Call

    Enclosed

    Company Update
    Intimation For The Schedule Of Investors/Analysts Call/Meet.

    Enclosed

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Copy of the news paper publication

    Company Update
    Analyst Investor Meet Call Transcript

    Enclosed

    Filed with BSE (scrip 531768); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 6 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Poly Medicure: common questions

    Answered from the figures on this page.

    Poly Medicure last traded at ₹1,654.50 (NSE, as of 18 Nov 2026). The last session moved it up 0.30%.

    Poly Medicure is valued at about ₹16,770 crore (NSE, as of 18 Nov 2026).

    Poly Medicure trades at a price-to-earnings ratio of 52.74 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Poly Medicure has traded between ₹1,182.00 and ₹2,024.00 over the past 52 weeks, to 18 Nov 2026. It is currently 56% of the way up that range.

    Poly Medicure (POLYMED) is classified under Pharma on this site's screener.